argenx SE

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0010832176
EUR
792.20
10.8 (1.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.90%

  • Poor long term growth as Operating profit has grown by an annual rate 25.03% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -227.81
2

With ROE of 22.71%, it has a Very Expensive valuation with a 8.33 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 49,194 Million ()

stock-summary
P/E

37.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.64

stock-summary
Return on Equity

22.71%

stock-summary
Price to Book

9.47

Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Sep 2014)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.78%
0%
29.78%
6 Months
55.46%
0%
55.46%
1 Year
34.68%
0%
34.68%
2 Years
89.84%
0%
89.84%
3 Years
105.71%
0%
105.71%
4 Years
211.28%
0%
211.28%
5 Years
236.53%
0%
236.53%

argenx SE for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
124.98%
EBIT Growth (5y)
25.03%
EBIT to Interest (avg)
-227.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.25
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
0
ROE (avg)
2.90%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
8.33
EV to EBIT
110.92
EV to EBITDA
104.98
EV to Capital Employed
21.54
EV to Sales
14.24
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
19.42%
ROE (Latest)
22.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by argenx SE"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 78.51% vs 190.25% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 382.19% vs 59.58% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,024.80",
          "val2": "1,134.30",
          "chgp": "78.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.90",
          "val2": "-314.20",
          "chgp": "86.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "0.80",
          "chgp": "187.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "20.90",
          "val2": "13.30",
          "chgp": "57.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "770.10",
          "val2": "-272.90",
          "chgp": "382.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-29.20%",
          "val2": "-367.80%",
          "chgp": "33.86%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,024.80
1,134.30
78.51%
Operating Profit (PBDIT) excl Other Income
-42.90
-314.20
86.35%
Interest
2.30
0.80
187.50%
Exceptional Items
20.90
13.30
57.14%
Consolidate Net Profit
770.10
-272.90
382.19%
Operating Profit Margin (Excl OI)
-29.20%
-367.80%
33.86%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 78.51% vs 190.25% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 382.19% vs 59.58% in Dec 2023

stock-summaryCompany CV
About argenx SE stock-summary
stock-summary
argenx SE
Pharmaceuticals & Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Company Coordinates stock-summary
Company Details
Willemstraat 5 , BREDA None : 4811 AH
stock-summary
Tel: 31 76 3030488
stock-summary
stock-summary
Registrar Details